Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azvudine in Chronic Hepatitis B
NCT07307586Phase 3Recruiting
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of azvudine in Chronic Hepatitis B (CHB) (3 arms). Primary endpoint: Follow-up at 12 months. Started Sep 2025; status: recruiting.
02
Drugs
azvudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07307586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07307586.